Clinical Trial Update: Dose-Escalation and Safety Trial of YN968D1 [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 dose-escalation and safety trial update for YN968D1 in cancer patients with solid tumors.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer
• Solid Tumors

Drugs mentioned

• YN968D1

Snippet

Sponsor: Elevar Therapeutics | Conditions: Cancer Patients With Solid Tumors | Phase 1, Phase 2 | Status: COMPLETED